SavedAdd your journal

Journals / İnönü Üniversitesi Tıp Fakültesi Dergisi / 2002 / Cilt: 9 - Sayı: 3

Comparision of efficiancy of piperaciline-tazobactam-amikacin combination versus meropenem-amikacin combination in febrile neutropenic patients

Febril nötropenik hastalarda piperasilin - tazobaktam-amikasin ve meropenem-amikasin etkinliklerinin karşılaştırılması

İrfan KUKU
İsmet AYDOĞDU
Mustafa BAYDAR
Lezzan KESKİN
Fahri ARI
Mustafa DİKİLİTAŞ
Emin KAYA
Pages
195–197
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

As a conclusion, two combinations were found to be equal in efficacy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In patients with febrile neutropenia unless proved otherwise, infections should be considered as the cause of fever and antibiotic treatment must be started immediately.
📊
Key Findings & Data:This study was designed to compare efficiency of empirically given piperaciline taxobactam+amikacin and meropenem+amikacin combinations in patients with FN. 51 patients followed and treated by Turgut Özal Medical Center, Department of Haematology were admitted to study.
💡
Conclusion & Impact:As a conclusion, two combinations were found to be equal in efficacy.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

In patients with febrile neutropenia unless proved otherwise, infections should be considered as the cause of fever and antibiotic treatment must be started immediately. This study was designed to compare efficiency of empirically given piperaciline taxobactam+amikacin and meropenem+amikacin combinations in patients with FN. 51 patients followed and treated by Turgut Özal Medical Center, Department of Haematology were admitted to study. As a conclusion, two combinations were found to be equal in efficacy.

Özet

Febril nötrepeni (FN) hastalarında ateşin varlığı aksi ispat edilinceye kadar enfeksiyon kaynaklı olduğu kabul edilip ampirik antibiyotik tedavisine hemen başlanılması gerekmektedir. Bu çalışma, FN hastalarında ampirik piperasilin-tazobaktam+amikasin ile meropenem+amikasin tedavisinin etkinliklerinin karşılaştırmak amacıyla planlanmıştır. Çalışmaya kliniğimizde takip edilen 51 hasta ve bu hastalarda gelişen 76 FN atağı değerlendirmeye alındı. FN atağı gelişen 40 hastaya ampirik meropenem+amikasin kombinasyonu, 36 hastaya tazobaktam+amikasin kombinasyonu verildi. Çalışma sonucunda her iki kombinasyon eşit etkinlikte bulunmuştur.

🔖

Cite This Article

KUKU, İ., AYDOĞDU, İ., BAYDAR, M., KESKİN, L., ARI, F., DİKİLİTAŞ, M., KAYA, E. (2022). Comparision of efficiancy of piperaciline-tazobactam-amikacin combination versus meropenem-amikacin combination in febrile neutropenic patients. İnönü Üniversitesi Tıp Fakültesi Dergisi, Cilt: 9 - Sayı: 3, 195–197. https://ajindex.com/articles/548939

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Kinnunen U, Syrjala H, Koskela M et al. Continuous-monitoring blood culture screening system improves the detection of bactcremia in neutropenic patients. Scand J Infect Dis 1996; 28: 287-92
  2. Rintala E. Incidence and clinical significance of positive blood cultures in febrile Episodes of patients with hematological malignancies Scand J Infect Dis 1994; 26(l):77-84
  3. Comctta A, Calandra T, Gaya II, Zinner SH, de Bock R, Del Favero A, at al. Monotherapy with meropenem versus combination therapy with ccftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and rreantment of Cancer and the Gruppo Italiano Malattie Ematologichc Maligne dell' Adulto Infection Program. Antimicreb Agents Chemother 1996 May;4()(5):1108-15
  4. Lindblad R, Rodjer S, Adriansson M, et al. Empiric monotherapy for febrile neutropenia-a randomized study comparing meropenem with ccftazidime. Scand J Infect Dis 1998;30(3):237-43
  5. Fcld R, Oe Pauw B, Berman S, Keating A, Ho W. Meropenem versus ccftazidimc in the treatment of cancer patients with febrile neutropenia: a randomized, double-blind trial. J Clin Oncol 200 Novl;18(21):369()-8
  6. Vandercam B, Gerain J, Humbler Y, Ferrant A, Wauters G, Moreau M, et al. Meropenem versus ceftazidimc as empirical monotherapy for febrile neutropenic cancer patients. Ann Hematol 2000 Mar;79(3):152-7
  7. Shah PM, Heller A, Fuhr HG, Walter F, Halir S, Schamann R, et al. Empirical monotherapy with meropenem versus imipenem/cilastatin for febrile episodes in neutropenic patients. Infection 1996 Nov-Dec;24(6):480-4
  8. Marie JP, Vekhoff A, Cony-Makhoul P, Fierc D, Guy H, Herbrecht R, et al. Piperacilline/tazobactam combination+amikacin versus ceftazidime+amikacin in patients with neutropenia and fever. Presse Med 1995 Feb25;24(8):397-401
  9. Marie JP, Marjanovic Z, Vekhoff A, Bouvet A, Chast F, Levy V, et al. Piperacilline/tazobactam plus tobramycin versus ceftazidim plus tobramycin as empiric therapy for fever in severely neutrupenic patients. Support Care Cancer 1999 Mar:7(2):89-94
  10. Figuera A, Rivero N, Pajuelo I'-', Font P, Lcyra F, de La Camara R, et al. Initial empiric therapy of febrile neutropenia with antibiotic monotherapy. Mcd Clin (Bare) 2001 May5;116(16):610-l
  11. Del Favero A, Menichctti F, Martino P, Bucaneve G, Micozzi A, Gentile G, ct al. A multicenter double-blind, placebo-controlled trial